FGFR3-Spectrum;FGFR3-Spektrum

Medizinische Genetik

Volumn 16, Issue 1, 2004, Pages 9-16

  Zabel, Bernhard ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Achondroplasia therapeutic approach; FGFR3; Growth plate; Signaling pathway; Skeletal dysplasia

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3;

ACHONDROPLASIA; BONE DEFECT; BONE DYSPLASIA; BONE GROWTH; CORRELATION ANALYSIS; GENE MUTATION; GENOTYPE; HUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN FUNCTION; RECEPTOR GENE; REVIEW;

EID: 1842587617     PISSN: 09365931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Aviezer D, Golembo M, Yayon A (2003) Fibroblast growth factor receptor 3 as a therapeutic target for achondroplasia - genetic short limbed dwarfism. Curr Drug Targets 4:353-365.
2. Brodie SG, Deng C-X (2003) Mouse models orthologous to FGFR3-related skeletal dysplasias. Pediatr Pathol Mol Med 22:87-103.
3. Cho JY, Guo C, Torello M, Lunstrum GP, Iwata T, Deng C, Horton WA (2004) Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. Proc Natl Acad Sci USA 101:609-614.
4. Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P (1996) Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84:911-921.
5. Goriely A, McVean GAT, Röjmyr M, Ingemarsson B, Wilkie AOM (2003) Evidence for selective advantage of pathogenic FGFR2 mutations in the male germ line. Science 301:643-646.
6. Hall CM (2002) International nosology and classification of constitutional disorders of bone (2001). Am J Med Genet 113:65-77
7. Hilbert M, Hilbert K, Spranger J, Wildhardt G, Winterpacht A, Wüchner C, Zabel B (1998) Hypochondroplasie, Achondroplasie und Thanatophore Dysplasie als Folge von Mutationen des Fibroblastenwachstumsfaktorrezeptor-3-Gens (FGFR3). Monatsschr Kinderheilkd 146:687-691.
8. Liu Z, Xu J, Colvin JS, Ornitz DM (2002) Coordination of chondrogenesis and osteogenesis by fibroblast growth factor 18. Genes & Dev 16:859-869.
9. Minina E, Kreschel C, Naski MC, Ornitz DM, Vortkamp A (2002) Interaction of FGF, Ihh/PthIh, and BMP signalling integrates chondrocyte proliferation and hypertrophic differentiation. Dev Cell 3:439-449.
10. Mohnike K, Klingebiel K-H, Zabel B, Hrsg. Achondroplasie und Hypochondroplasie. Diagnostik und Betreuung von Kindern mit spezifischen Kleinwuchsformen. Palatium, Mannheim, 2001.
11. Ornitz DM, Marie PJ (2002) FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease Genes & Dev 16:1446-1465
12. Rauchenberger R, Borges E, Thomassen-Wolf E, Rom E, Adar R, Yaniv Y, Malka M, Chumakov I, Kotzer S, Resnitzky D, Knappik A, Reiffert S, Prassler J, Jury K, Waldherr D, Bauer S, Kretzschmar T, Yayon A, Rothe C (2003) Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3. J Biol Chem 278: 38194-38205.
13. Sahni M, Ambrosetti DC, Mansukhani A, Gertner R, Levy D, Basilico C (1999) FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes & Dev 13:1361-1366
14. Shiang R, Thompson LM, Zhu Y-Z, Church DM, Fiedler TJ, Bocian M, Winokur ST, Wasmuth JJ (1994) Mutations in the transmembrane domain of FGFR-3 causes the most common genetic form of dwarfism, achondroplasia. Cell (United States), Jul 29 1994, 78(2) p335-42.
15. Spranger J (1985) Pattern recognition in bone dysplasias. In: CJ Papadatos & CS Bartsocas Hrsg. Endocrine genetics and genetics of growth. Liss, New York, pp315-342.
16. Stanton LA, Underhill TM, Beier F (2003) MAP kinases in chondrocyte differentiation. Dev Biol 263:165-175.
17. Toydemir R, Longo N, Brassington A, Bayrak-Toydemir P, Krakowiak P, Jorde LB, Bamshad M (2003) A new syndrome caused by a novel loss-of-function mutation in FGFR3. Am J Hum Genet 73(Suppl):171.
18. Vajo Z, Francomano C, Wikin DJ (2000) The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: The achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocrine Reviews 21:23-39.
19. Webster MK, Donoghue DJ (1997) FGFR activation in skeletal disorders: too much of a good thing. Trends Genet 13:178-182.
20. Yasoda A, Komatsu Y, Chusho H, Miyazawa T, Ozasa A, Miura M, Kurihara T, Rogi T, Tanaka S, Suda M, Tamura N, Ogawa Y, Nakao K (2004) Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat Med 10:80-86.